Form 4: Mirum Pharmaceuticals Director Timothy Walbert Reports Equity Compensation and Vesting

Mirum Pharmaceuticals, Inc. Director Timothy P. Walbert reported the acquisition of common stock through RSU vesting and the grant of new stock options and restricted stock units.

Summary

• Timothy P. Walbert, a Director at Mirum Pharmaceuticals, Inc. (MIRM), reported transactions on May 29, 2025, related to his equity holdings.
• He acquired 5,703 shares of common stock through the vesting and conversion of previously granted restricted stock units.
• He was granted 6,268 stock options with an exercise price of $44 per share; these options will vest on the first anniversary of the grant date or fully by the Issuer's 2026 annual stockholder meeting and are set to expire on May 28, 2035.
• Additionally, he was granted 3,977 new restricted stock units, which will vest on the first anniversary of the grant date or fully by the Issuer's 2026 annual stockholder meeting.

Sentiment

Score: 5

Explanation: The document is a routine insider transaction disclosure, which is neutral in sentiment. It reflects standard equity compensation practices and does not contain information that would significantly alter the company's perceived financial health or operational outlook.

Positives

• The grant of new stock options and restricted stock units to a director aligns their interests with long-term shareholder value, as the value of these awards is tied to the company's stock performance.

Negatives

• No direct negative implications are apparent from this routine insider transaction disclosure.

Future Outlook

NA

Industry Context

This filing represents a routine disclosure of insider equity compensation, a common practice across all industries for publicly traded companies. Such grants are standard components of executive and director compensation packages, designed to incentivize long-term performance and align management interests with those of shareholders.

Related Party Transactions

• Timothy P. Walbert, a Director of Mirum Pharmaceuticals, Inc., engaged in transactions involving the company's equity securities, which are considered related party transactions due to his insider status.

Stakeholder Impact

• Shareholders: The grant of equity awards to a director aligns their interests with shareholder value creation, as the value of these awards is tied to the company's stock performance.

Next Steps

• Vesting of 6,268 stock options on the first anniversary of the grant date or fully by the Issuer's 2026 annual stockholder meeting.
• Vesting of 3,977 restricted stock units on the first anniversary of the grant date or fully by the Issuer's 2026 annual stockholder meeting.

Key Dates

Keywords

Mirum Pharmaceuticals, MIRM, SEC Form 4, Insider Trading, Stock Options, Restricted Stock Units, Director Compensation, Equity Grant, Timothy Walbert